Shares of CureVac (CVAC) gained 2.6% in premarket trading on Thursday after the company said it began dosing participants in a Phase 1 clinical trial assessing an experimental mRNA-based influenza vaccine it developed with GlaxoSmithKline (GSK.LN). The open-label study plans to enroll 240 adults. CureVac had previously tried to develop a COVID-19 vaccine but instead decided last year to scrap those plans and instead focus on developing a second-generation COVID-19 shot with GSK. CureVac's stock has tumbled 83.7% over the past year, while the broader S&P 500 is up 17.3%.
(END) Dow Jones Newswires
02-10-22 0716ETCopyright (c) 2022 Dow Jones & Company, Inc.